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Vascular cell adhesion molecule (VCAM)-1 expression
may be coupled to redox-sensitive regulatory pathways,
and iron may play a role in generation of reactive oxy-
gen species that participate in these signaling pathways.
To investigate the role of iron in TNFa-induced VCAM-
1 gene expression, human dermal microvascular en-
dothelial cells (HDMEC) were stimulated with TNFa
in the presence of iron chelators and examined for ex-
pression of VCAM-1. The iron chelators dipyridyl (DP)
and desferoxamine (DFO) inhibited VCAM-1 protein
and mRNA induction in a concentration- and time-
dependent manner. The induction of VCAM-1 was not
inhibited by nonmetal binding reactive oxygen species
(ROS) scavengers, implying a direct e¡ect of iron
in the expression of these adhesion molecules. The
e¡ect of iron was mediated at the level of gene tran-
scription since pretreatment with DP abrogated the
TNFa-mediated up-regulation of VCAM-1 hetero-
geneous nuclear RNA. Pretreatment of HDMEC with
DP prior to TNFa treatment had no e¡ect on p65
nuclear localization, DNA binding, or serine phosphory-
lation. DP pretreatment inhibited TNFa- and IFNc-
mediated interferon regulatory factor 1 (IRF-1) protein
expression, although restoration of IRF-1 expression
failed to reconstituteVCAM-1 expression. DP treatment
also blocked VCAM-1 induction in human umbilical
vein endothelium and blocked induction of a host
of NF-kB activated genes in HDMEC including
ICAM-1, IL-8, and tissue factor. IkBa, an NF-kB indu-
cible and constitutively accessible gene not requiring
chromatin remodeling for transcription, was not
a¡ected by DP treatment. These data suggest that iron
plays a critical role in TNFa mediated VCAM-1 induc-
tion in HDMEC, and the target for iron e¡ects may be
IRF-1, NF-kB, and potentially chromatin remodeling.
Keywords: Endothelium/gene regulation/adhesion/iron. J Invest
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V
ascular cell adhesion molecule 1 (VCAM-1) is an
inducible adhesion protein that mediates hetero-
typic adhesive events within cells expressing the
a4b1 (VLA-4) integrin receptor (Elices et al, 1990).
VCAM-1 is minimally expressed in endothelial cells
(EC) in normal skin. However, VCAM-1 is induced in injury
or in a variety of cutaneous in£ammatory disorders including
psoriasis, atopic dermatitis, delayed type hypersensitivity reac-
tions, late phase reactions, and graft vs. host disease (Norris et al,
1991; Norton and Sloane, 1991; Groves et al, 1993; Das et al, 1994;
Onuma, 1994;Wakita et al, 1994; Litch¢eld et al, 1996). In experi-
mental models of cutaneous in£ammation, blockade of the
VCAM-1/VLA-4 binding pathway resulted in diminution of cuta-
neous in£ammatory responses, further supporting an important
functional role of VCAM-1 (Silber et al, 1994).
The induction of VCAM-1 by pro-in£ammatory cytokines
can be blocked by a variety of agents with antioxidant activity
(Marui et al, 1993). The mechanism of this e¡ect is not fully de-
¢ned, although evidence points to involvement of redox- regula-
tion of the activity of transcription factors such as NF-kB. The
modulation of redox-sensitive protein kinases and transcription
factors by reactive oxygen species (ROS) has previously been
suggested to be a central and early event in the induction of in-
£ammatory reactions (Baeuerle and Henkel, 1994). Oxidative
stress has also been linked to cutaneous in£ammatory disorders
such as psoriasis, contact dermatitis and ultraviolet-induced skin
changes (Sharkey et al, 1991; Lontz et al, 1995; Brenneisen et al,
1998). In addition, ROS released by in£ammatory cells and kera-
tinocytes have been suggested to serve as second messengers in
redox-sensitive signal transduction processes (Allen and Tresini,
2000).
Iron, like oxygen, is both physiologically essential and bio-
chemically dangerous (McCord, 1998). Within the body, iron is
tightly bound and regulated. Like other transition metals, iron
has the capacity to act as a catalyst generating reactive oxygen
species that may damage biologic macromolecules. Certain stimuli
that induce cell and tissue damage are known to release iron from
their normal protective carriers. For example, UV light induced
in£ammation and DNA damage may be dependent upon UV-
mediated release of iron from carrier proteins such as ferritin
(Pourzand et al, 1999). Like other transition metals, iron also has
the capacity to act as a catalyst, generating reactive oxygen species
that in turn damage biologic macromolecules. Iron may exert
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biological e¡ects via generation of ROS such as the highly toxic
hydroxyl radical (HO  ), which may then act as an intracellular
second messenger (Schreck et al, 1991). One potential target for
hydroxyl radicals is activation of NF-kB (Schreck et al, 1991).
This study was undertaken to address the question of whether
iron, via e¡ects on NF-kB activation, plays an important role in
the cytokine induction of VCAM-1 in dermal microvascular en-
dothelial cells.We have determined that removal of iron inhibits
TNFa-mediated induction of VCAM-1 expression in dermal en-
dothelial cells; this inhibition was not mediated by e¡ects on NF-
kB nuclear translocation or DNA binding, but was associated
with decreased VCAM-1 gene transcription.
MATERIALS AND METHODS
Cell culture Both primary cultures of human dermal microvascular
endothelial cells (HDMEC), obtained from Emory Skin Diseases
Research Center, and HDMEC immortalized with SV40 Large T (5A32
cells) were utilized. Cells were isolated and passaged as described
previously (Ades et al, 1992; Swerlick et al, 1992a). Cells were grown in
£asks coated with 0.1% gelatin in MCDB 131 media (Mediatech,
Herndon,VA) supplemented with 10% (v/v) fetal bovine serum (Hyclone,
Logan, Utah), 1% penicillin/streptomycin (Mediatech), 2 mM L-glutamine
(Mediatech), 0.25 mg/ml cAMP and 1 mg/ml hydrocortisone (Sigma, St.
Louis, MO) and maintained at 371C in a humidi¢ed atmosphere of 5% CO2.
Reagents and antibodies The iron chelators, 2,2-dipyridyl (DP), a
soluble chelator of ferrous iron (Fe2þ ), and desferoxamine (DFO), which
binds ferric iron (Fe3þ), were obtained from Sigma. 5, 5 dimethyl-
1-pyrroline n-oxide (DMPO), a spin trapper without metal bind-
ing capability, and 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), a
nitroxide spin trap that can maintain iron as Fe3þ, were also purchased
from Sigma. Recombinant human TNFa and IFNg were purchased from
R & D Systems, Inc. (Minneapolis, MN). Anti-IRF-1 antibody was
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and
rabbit polyclonal antip65 and antip50 antibodies were purchased from
Biodesign International (Saco, ME). Anti-phospho-p65 (Ser 536) antibody
was purchased from Cell Signaling Technology, Inc (Beverly, MA). The
VCAM-1 P8B1 monoclonal antibody developed by E.A. Wayner and
T. LeBien was obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and maintained by
The University of Iowa.
Cell surface ELISA ELISA using anti-VCAM-1monoclonal antibodies
P3C4 (generous gift of Dr. Elizabeth Wayner) or derived from the VII-
6G10 hybridoma (ATCC, Rockville, MD), or using anti-ICAM-1
monoclonal antibody 84H10 (generous gift from Dr. Stephen Shaw) was
performed as previously described (Ades et al, 1992; Swerlick et al, 1992b).
The cells were treated with DP at doses ranging from 125 to 1000 mM for
0^24 h followed by 16 h of TNFa. Brie£y, the cells were incubated with
primary antibodies for one hour, ¢xed with 2% formaldehyde, and
washed with Hanks bu¡er (with calcium and magnesium). Secondary
antibody (goat antimouse HRP conjugate, Bio-Rad, Hercules, CA) was
incubated for one hour and then washed thoroughly with Hanks bu¡er
(with calcium and magnesium). Color was developed using DAKO TMB
solution for 5^30 min, the reaction stopped, and then the plate read with
an ELISA reader (Microplate Autoreader Bio-Tek Instruments EL 311 s)
at O.D. 450 nm. Figures represent one representative experiment, and all
were repeated at least three times. Bars represent the mean OD of four
wells7 SD.
Flow cytometric analysis Cell surface expression of VCAM-1 was
examined in HDMEC by £ow cytometric analysis as previously described
(Swerlick et al, 1992b). Brie£y, HDMEC were stained for VCAM-1
expression before and after TNFa (1000 m/ml) for 16 h. Cells were
trypsinized, aliquotted, pelleted and stained with anti VCAM-1
monoclonal antibody (P1B8, Hybridoma databank) followed by FITC
conjugated goat antimouse IgG antibody (Caltag, Burlingame, CA). Mean
channel £uorescence was determined for each data point using a minimal
of 10000 events. Cell viability was determined by simultaneous staining
with propidium iodide.
Measurement of VCAM-1 mRNA and heterogeneous nuclear
VCAM-1 RNA (hnRNA) expression HDMEC were treated with
125^500 mM DP for 24 h followed by 200 U/ml TNFa for 24 h. Total
RNA was isolated with TriReagent (Sigma) from 5A32 HDMEC
according to manufacturer’s instructions. cDNA was prepared using the
Superscript Preampli¢cation System for 1st Strand cDNA Synthesis
(Gibco/BRL, Carlsbad, CA) using the random primer protocol. Real-
time polymerase chain reaction (PCR) was done using SYBR green
technology with Perkin-Elmer 5700 Gene-Amp Detection System with
VCAM-1 primers (forward sequence 50 -CAT GGA ATT CGA ACC
CAA ACA-30 and reverse sequence 50 -GGC TGA CCA AGA CGG TTG
TATC-30). Data was normalized with primers for a housekeeping gene.
Relative quantities were determined by generating a standard curve from
dilutions of cDNA containing the message of interest. Data was then
expressed as fold increase over control. Experiments were repeated at least
three times, and data shown are a single representative study.
VCAM-1 hnRNA expression was measured to assess the e¡ect of iron
chelation on the transcription of the VCAM-1 gene using a modi¢cation
of the above technique (Elferink and Reiners, 1996). Prior to reverse
transcription, total RNAwas treated with RNAse-free DNAse for 1 h at
room temperature to destroy any potential contaminating genomic DNA.
DNAse was inactivated by heating at 751C for 20 min VCAM-1 primers
were selected that would amplify only nascent, unspliced hnRNA
(forward sequence 50 -TAC AGT GTT ACT TCT TCT TCC ACA TTC
AA-30 located at the intron between exon 6 and 7 and reverse sequence
50 -GCC TCA TGA CTC ACT TTA ACC AATT-30 located at the intron
between exon 6 and 7). Emory University Microchemical Facility
synthesized all primers.
Electrophoretic mobility-shift assay (EMSA) Con£uent 5A32
HDMEC were treated with 500 U/ml TNFa for 2 h after preincubation
with 500 mM DP for 24 h. Nuclear proteins were extracted and EMSA
performed as described previously (Gille et al, 1996). The VCAM-1
oligonucleotide was synthesized to encompass the two NF-kB-like sites
of the human VCAM-1 promoter. The double stranded oligonucleotide
was 50 -end labeled using the forward reaction with T4 polynucleotide
kinase (Gibco/BRL). The DNA binding reaction was performed under
the conditions described previously (Gille et al, 1996).
The speci¢city of NF-kB binding complex was further resolved
using competition with a cold unlabeled VCAM-kB oligonucleotide,
antibodies recognizing p50, p65 (Biodesign International, Saco, ME), or
phosphoserine (Calbiochem, San Diego, CA). Competitor and antibodies
were added 20 min before adding the radiolabeled probe to the binding
reaction. Samples were subjected to electrophoresis on a native 4%
polyacrylamide gel for 4 h at 120 V. Experiments were repeated at least
three times, and data shown are a single representative study.
Western blot Cells were washed with PBS twice and whole cell extracts
were prepared by lysing cells in 50 mM,Tris pH 8.0, 150 mM NaCl, 0.02%
Na Azide, 1 mg/ml Aprotinin, 1% Triton X, 1 mM PMSF. NaF was added
for the phosphoserine studies (Woetmann et al, 1999). The suspension was
centrifuged at 12,000 rpm for 15 min at 41C, and the protein in the
supernatant was quanti¢ed using the BioRad DC Protein Assay. Whole
cell protein extract was resolved with SDS-PAGE using a 10%
polyacrylamide gel and reducing conditions. After transfer to Hybond
ECL nitrocellulose (Amersham Pharmacia Biotech), the protein was
stained with Ponceau S (Sigma) to verify uniform loading and transfer.
Membranes were blocked with 5% BSA in TBS-T (50 mM Tris-Cl pH
7.4, 150 mM NaCl, 0.1% Tween 20, pH 7.4) overnight and subsequently
incubated with primary antibodies (IRF-1 Ab 1:500, anti-p65 Ab 1:2000,
anti-phosphoserine 536 p65 Ab 1:1000) for 1h at room temperature. The
membrane was washed with TBS-T three times and incubated for 1 h at
room temperature with the appropriate horseradish peroxidase-conjugated
secondary antibody. Subsequently, the membrane was washed three times
withTBS-Tand analyzed by enhanced chemiluminescence (ECL Reagent,
Amersham Pharmacia Biotech).
Immuno£uorescence microscopy All cells were grown overnight on
eight-well chamber slides (Nalge Nunc International, Naperville, IL)
before treatment. Designated wells were left untreated or treated with DP
for 24 h, DP followed by stimulation with TNFa 500 U/ml for 30 min, or
TNFa alone. The cells were washed with PBS twice for 5 min each and
¢xed with 3.7% para-formaldehyde for 20 min at room temperature. The
cells were washed again and permeabilized with 0.2% Triton X-100 for 10
min at room temperature. The cells were washed and blocked with PBS
with 10% FBS at room temperature for at least 10 min. After blocking,
the cells were incubated with anti-p65 rabbit antibody (Biodesign) at
1:300 for 1 h at room temperature. The cells were washed three times with
blocking solution before adding goat antirabbit FITC conjugated (Caltag,
Burlingame, CA) secondary antibody to each well and incubating for 1 h at
room temperature in the dark. The cells were washed three times with
PBS, mounting reagent added, and the slides visualized with £uorescent
microscopy using a Leica DMR-E £uorescence microscope equipped with
a Hammamatsu Orca camera. Images were captured and processed using
Open Lab software (Improvision Inc., Lexington, MA).
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RESULTS
Iron chelators inhibit VCAM-1 induction in HDMEC
When endothelial cells were preincubated with 2,2-dipyridyl
(DP), a ferrous iron chelator, and then stimulated with TNFa at
a dose and for a duration which had been shown previously to
maximally induce VCAM-1 expression in HDMEC (Ades et al,
1992; Swerlick et al, 1992b), VCAM-1 protein expression was
inhibited in a concentration- and time-dependent manner.
Maximal inhibition was observed at doses as low as 500 mM
(Fig 1A). Partial inhibition was observed when DP was added
concurrently with TNFa stimulation, with increasing inhibition
observed after 8 h (470%), and complete inhibition requiring at
least a 24-h preincubation (Fig 1B). Identical inhibition was
observed when expression of induced VCAM-1 was examined
by £ow cytometric analysis (Fig 1C). No signi¢cant decreases in
cell viability were noted, even with treatment of cells up to 24 h
with doses of DP up to 4 mM when examined by £ow
cytometric analysis or trypan blue exclusion (data not shown).
In order to address whether the DP-mediated inhibition of
VCAM-1 induction was mediated via iron chelation, we exam-
ined the e¡ect of a di¡erent iron-speci¢c chelator, desferoxamine
(DFO), on TNFa-mediated induction of VCAM-1. VCAM-1
protein expression was again inhibited in a concentration-
dependent fashion (Fig 2A) with 50% inhibition of TNFa-
induced VCAM-1 expression seen at 500 mM, and maximal
inhibition noted at 2000 mM. DFO is less cell-permeable than
DP, which probably accounts for the need for higher doses for
comparable e¡ects. When exogenous iron in the form of ferric
citrate (2000 mM) was combined with DFO prior to preincuba-
tion, inhibition of TNFa-mediated VCAM-1 induction was
partially reversed (Fig 2B). In addition, when 5A32 HDMEC
were treated with TEMPO, a nitroxide spin trap that maintains
iron as Fe3þ (Voest et al, 1993), and then stimulated with TNFa,
VCAM-1 induction was also inhibited in a concentration-
dependent fashion (Fig 2D). However, DMPO, a spin trap
without metal binding capability (Rosen and Rauckman, 1984)
did not inhibit TNFa induced VCAM-1 up-regulation (Fig 2C).
These results further support a role for iron in expression of
VCAM-1.
Inhibition of VCAM-1 induction is not cell- or gene-
speci¢c To determine whether the DP mediated inhibition was
gene or cell-speci¢c, we examined the e¡ect of DP pretreatment
onTNFa mediated VCAM-1 induction in human umbilical vein
endothelial cells (HUVEC) and on TNFa mediated ICAM-1
induction in HDMEC. DP inhibited VCAM-1 induction of
VCAM-1 in HUVEC in a dose dependent manner virtually
identical to that observed in HDMEC. Unlike the case for
VCAM-1 expression, 8 h of pretreatment with DP (500 mM) had
virtually no e¡ect on ICAM-1 cell surface expression. However,
preincubation of cells with DP for 24 h resulted in marked
inhibition of ICAM-1 protein expression (Fig 3).
Iron chelators inhibit VCAM-1 gene transcription In order
to examine whether inhibition of VCAM-1 expression may be
mediated by changes in gene expression, we initially examined
whether DP pretreatment prior to TNFa stimulation inhibited
TNFa-mediated increases in VCAM-1 mRNA expression. DP
pretreatment inhibited up-regulation of VCAM-1 mRNA by
490% (Fig 4A). Similarly, DFO almost completely inhibited
TNFa-mediated increases in VCAM-1 mRNA levels (Fig 4B).
In contrast, the nonmetal binding spin trap DMPO had no
e¡ect, consistent with its lack of e¡ect on TNFa induced
VCAM-1 protein expression (Fig 4B).
In order to directly examine whether iron chelators inhibit
VCAM-1 expression by inhibition of VCAM-1 gene transcription,
we utilized real time PCR to measure the expression of VCAM-1
hnRNA after cytokine stimulation in the presence and absence of
the iron chelator DP. PCR primer pairs were designed that
recognized intronic sequences that are found only in unspliced
VCAM-1 hnRNA. Treatment of cells with TNFa resulted in a
marked induction of hnRNA that was inhibited by pretreat-
ment with actinomycin D or DP (Fig 5). These data provide
support for VCAM-1 gene transcription as being the target for
iron chelator mediated inhibition of VCAM-1 expression.
Figure1. DP pretreatment blocks TNFa-mediated VCAM-1 induc-
tion in 5A32 HDMEC in a dose and time-dependent manner.
HDMEC were pretreated with DP before stimulation with TNFa and
cell-surface VCAM-1 measured by ELISA. (A) 5A32 HDMEC were pre-
treated with increasing doses of DP for 8 or 24 h as indicated followed by
500 U/ml TNFa for 16 h. (B) 5A32 HDMEC were pretreated with 500 mM
DP for times ranging from 0 to 24 h and then stimulated with 500 U/ml
TNFa for 16 h. (C) Flow cytometric analysis of 5A32 HDMEC: Untreated
(A), DP 1000 mM 24 h (B), TNFa 1000 U/ml16 h (C), and DP treated
(1000 mM 24 h) followed byTNFa (1000 U/ml16 h).
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Iron chelators do not inhibit NF-kB translocation or DNA
binding Iron chelators have been shown to regulate the
stability of transcription factors (Wang and Semenza, 1993; Lin
et al, 1997). Previous studies have also demonstrated that certain
antioxidants may also block translocation of activated NF-kB
complexes from the cytoplasm to the nucleus, thus inhibiting
NF-kB mediated gene activation (Bowie et al, 1997). We
hypothesized that iron chelator-mediated inhibition of VCAM-1
induction may be controlled via e¡ects on NF-kB stability or
function. In order to test this hypothesis, we examined nuclear
localization of NF-kB complexes after TNFa stimulation using
immuno£uorescence microscopy. TNFa stimulation of HDMEC
resulted in prompt translocation of p65 from the cytoplasm to
the nucleus. However, DP pretreatment prior to TNFa had
no detectable e¡ect on this TNFa-mediated p65 translocation
(Fig 6).
It was possible that although DP pretreatment may not a¡ect
NF-kB translocation, DP may alter the ability of translocated
complexes to bind to relevant sequences in the VCAM-1
promoter. In order to examine whether DP pretreatment
resulted in loss of NF-kB binding activity despite apparently
normal translocation, nuclear extracts were examined for protein
binding to the VCAM-1 NF-kB sequence using EMSA (Fig 7).
DP treatment had no e¡ect on the binding of translocated
NF-kB complexes. After TNFa stimulation (lanes 3^8),
complex formation was the same in both DP pretreated (lanes
6^8) and untreated samples (lanes 3^5). New complex formation
(bands A and B, lanes 3 and 6), which was shifted with addition
of antip50 (band C, lanes 4 and 7) or antip65 (band D, lanes 5
and 8) antibodies was also identical in each case. These data
would suggest that the DP e¡ect is mediated via targets other
than NF-kB translocation or DNA binding.
Iron chelators inhibit TNFa-mediated IRF-1 induction The
previous data suggested that the e¡ect of DP on VCAM-1 gene
transcription may be mediated via an NF-kB independent
mechanism. Another potential target is interferon regulatory
factor 1 (IRF-1), a transcription factor that is also induced
by TNFa. In addition to the tandem NF-kB elements in
the VCAM-1 promoter, optimal transcriptional induction of
VCAM-1 depends to some degree upon binding of IRF-1 to a
distinct and adjacent element in the VCAM-1 promoter (Neish
et al, 1995; Lechleitner et al, 1998). In order to examine whether
iron chelation blocks IRF-1 expression, we examined IRF-1
protein expression after cytokine stimulation with and without
DP pretreatment. Treatment of HDMEC with either TNFa
or IFNg induced expression of IRF-1 protein. Pretreatment
of 5A32 HDMEC with DP prior to either TNFa or IFNg
treatment completely inhibited the expression of IRF-1
protein expression. This inhibition was dependent upon DP
concentration and preincubation time, roughly paralleling DP
e¡ects on VCAM-1 induction. Thus, DP may inhibit VCAM-1
induction via inhibition of IRF-1 induction (Fig 8A).
In order to examine whether the DP mediated inhibition of
VCAM-1 induction was primarily mediated via e¡ects on IRF-1
expression, we preinduced IRF-1 expression in 5A32 cells with
IFNg. By doing so, we were able to induce persistent IRF-1
expression without inducing VCAM-1 and IRF-1 expression
persisted for up 8 h, even after the addition of DP. HDMEC
were then treated with TNFa, with and without DP
pretreatment (Fig 8B). We then utilized cell based ELISA to
determine whether preinduction of IRF-1 by IFNg could
restore VCAM-1 induction by TNFa. However, induction of
IRF-1 with IFNg prior to DP treatment only partially restored
TNFa-mediated VCAM-1 induction (Fig 8C). These data
Figure 2. Iron chelation activity is required forVCAM-1 blockade. (A) 5A32 cells were pretreated with increasing concentrations of the iron chelator
DFO for 4 h prior to stimulation withTNFa (100 U/ml16 h). Cell surfaceVCAM-1 expression was measured by ELISA. (B) DFO- mediated inhibition of
VCAM-1 induction was partially reversed when cells were pretreated with 200 mM DFO plus ferric citrate (2000 mM 4 h) and stimulated withTNFa (500
U/ml16 h). 5A32 HDMEC were pretreated with the indicated concentrations of DMPO (C) and TEMPO (D) for 2 h and were stimulated with TNFa
(500 U/ml16 h). TNFa-mediatedVCAM-1 expression was blocked in a dose-dependent manner byTEMPO, a metal binding spin trapper that can main-
tain iron as Fe3þ, but not by DMPO, a nonmetal binding spin trapper, providing further support for a role of iron in VCAM-1 expression in 5A32
HDMEC.
874 KOO ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
suggest that although inhibition of IRF-1 expression by DP may
play a partial role in DP mediated-VCAM-1 inhibition additional
targets for DP e¡ect needed to be de¢ned.
Iron chelators do not inhibit NF-kB phosphorylation
Previous studies have suggested that changes in NF-kB phos-
phorylation, particularly at serine residues, may be critical for
the ability of NF-kB proteins, particularly p65, to transactivate
genes without a¡ecting DNA binding (Wang and Baldwin,
1998; Wang et al, 2000). To examine whether DP pretreatment
inhibited p65 phosphorylation, we utilized antibody in western
analysis that speci¢cally recognized serine-phosphorylated p65.
Under basal conditions, some p65 was constitutively phos-
phorylated and TNFa stimulation resulted in a prompt increase
in the level of phosphorylation. Pretreatment of HDMEC
with DP had no e¡ect on constitutive phosphorylation or the
increases associated with TNFa treatment (Fig 9).
Iron chelators inhibit cytokine induction of NF-kB genes
with delayed kinetics, but not IkBa Despite blocking
the TNFa mediated induction of VCAM-1 and ICAM-1, DP
appeared to have not discernable e¡ect on NF-kB translocation,
binding, or phosphorylation that might a¡ect its transactivating
function. Alternative targets requiring iron are mechanisms
regulating chromatin structure and availability of promoters
of NF-kB responsive genes. Previous studies have shown that
genes that are rapidly activated after cytokine stimulation, such
as IkBa, do not require chromatin modi¢cation for transcription
factor accessibility (Saccani et al, 2001; Saccani et al, 2002).
In order to examine whether DP may a¡ect VCAM-1 expression
via this target, we examined the TNFa induction of both
genes with constitutively and immediately accessible (CIA) pro-
moters (IkBa) and those with delayed inductions that presum-
ably require stimulus-dependent modi¢cations in chromatin
structure to make NF-kB sites accessible (Saccani et al, 2001;
Saccani et al, 2002). DP pretreatment blocked induction of
mRNA of two additional NF-kB regulated genes, interleukin-8
(Fig 10) and tissue factor (data not shown), in HDMEC.
In contrast, DP had no e¡ect on the TNFa mediated up-
regulation of IkBa mRNA (Fig 10). These data are consistent
with DP targeting cytokine-mediated e¡ects on chromatin
packaging.
Figure 3. DP mediated inhibition is not cell- or gene speci¢c: (A)
HUVEC were pretreated with DP (30^1000 mM) prior to stimulation with
TNFa (1000 U/ml16 h). Cells were assayed for VCAM-1 expression by
cell based ELISA. (B) 5A32 HDMECwere pretreated with various concen-
trations of DP for 8 or 24 h followed by 500 U/ml TNFa for 16 h. Cell-
surface levels of ICAM-1were measured by ELISA. Preincubation of cells
with DP for 24 h prior to cytokine treatment signi¢cantly blocked TNFa-
mediated ICAM-1 induction.
Figure 4. DP and DFO but not DMPO inhibits TNFa-mediated
VCAM-1 mRNA up-regulation. (A) 5A32 HDMEC were pretreated
with 250 or 125 mM DP for 24 h and then stimulated with 200 U/ml TNFa
for 24 h.VCAM-1mRNAwas measured by quantitative RT-PCR and dif-
ferences represented as fold increase over baseline. (B) Con£uent mono-
layers of 5A32 HDMEC were pretreated with 500 mM DP, 500 mM DFO,
or 500 mM DMPO for 24 h and then stimulated with 200 U/ml TNFa for
24 h. DP and DFO inhibit TNFa-mediated increases inVCAM-1mRNA,
but DMPO did not.
Figure 5. DP inhibits TNFa-mediated VCAM-1 expression by inhi-
bition of VCAM-1 gene transcription. 5A32 HDMEC were pretreated
with 500 mM DP for 8 h or 2 mg/ml actinomycin D for 30 min prior to
stimulation with 500 U/ml TNFa for 4 h. The fold di¡erences of VCAM-
1 hnRNAwere determined by quantitative RT-PCR. Results are represen-
tative of three experiments.
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DISCUSSION
Iron has been implicated as a key participant in a variety of in-
£ammatory disorders and processes. Studies examining the e¡ect
of iron chelators on the function of key transcription factors such
as NF-kB and HIF-1a have shown that chelation of iron a¡ects
proteasomal processing, resulting in inhibited degradation (Wang
Figure 6. DP does not a¡ect NF-kB translocation after TNFa
stimulation in 5A32 HDMEC cells. (A) Untreated cells; or (B) treated
with 500 U/ml TNFa for 30 min; (C) 500 mM DP for 24 h; and (D) 500
U/ml TNFa for 30 min after pretreatment with DP 500 mM for 24 h.
Cellular localization of p65 was identi¢ed by immuno£uorescence
microscopy.
Figure 7. DP does not a¡ect NF-kB binding to theVCAM-1 kB ele-
ment afterTNFa stimulation. 5A32 HDMECwere stimulated with 500
U/ml TNFa for 2 h with or without pretreatment with DP (500 mM) for 24
h.Nuclear extractswere assessed for the bindingof NF-kB by EMSA.TNFa
treatment results in appearance of complexes A and B, which appear in
cells regardless of whether pretreated with DP. In addition, both bands are
supershifted in treated cells by antip50 antibody (band C) or antip65 anti-
body (band D) with or without DP pretreatment.
Figure 8. Pretreatment of 5A32 HDMEC cells with IFNc prior
to DP pretreatment induces persistent IRF-1 expression but only
partially restores TNFa-mediated VCAM-1 induction. (A) 5A32
HDMECwere pretreated for 4, 8 and 24 hwith 1000 mM DP prior to TNFa
stimulation. Cell lysates were assayed for the presence of IRF-1 byWestern
blotting. Untreated cells (lane 1), DP treated (500 mM 24 h, lane 2),TNFa
treated (500 U/ml 2 h, lane 3) or 2 h of TNFa treatment preceded by
incubations of DP (500 mM) for 4 h (lane 4), 8 h (lane 5), and 24 h (lane 6).
(B) IFNg induces IRF-1 expression that persists after DP treatment. Un-
treated cells (lane 1), IFNg (1000 U/ml) for 2 h (lane 2), IFNg (1000 U/ml)
for 10 h (lane 3), IFNg (1000 U/ml) 2 h followed by DP (1000 mM) for 8 h
(lane 4), and IFNg (1000 U/ml) for 2 h followed by DP (1000 mM) for 24 h
(lane 5). Cell lysates were prepared and assessed for the presence of IRF-1
by Western blotting. (C) Prior induction of IRF-1 by IFNg does not re-
store VCAM-1 induction inhibited by DP pretreatment as measured
by ELISA. Control cells (untreated), IFNg (1000 U/ml  24 h), DP
(500 mM 24 h), IFN/DP (IFNg 1000 U/ml 2 h followed by DP
500 mM 24 h), TNFa 500 U/ml16 h), IFN/TNF (IFNg 1000 U/ml
2 h then TNFa 500 U/ml16 h), DP/TNF (DP 200 mM 6 h then TNFa
500 U/ml16 h), and IFN/DP/TNF (IFNg 1000 U/ml 2 h, then DP
500 mM 6 h, thenTNFa 500 U/ml16 h). Pretreatment of the cells with
IFNg and induction of IRF-1 expression prior to DP pretreatment only
partially restores TNFa-mediated VCAM-1 induction.
Figure 9. DP does not globally inhibit serine phosphorylation of
p65. 5A32 HDMEC cells were pretreated for 20 h with 500 mM of DP
prior to stimulation with 500a U/ml TNFa for 30 min Cell lysates (A)
untreated HDMEC (B) TNFa 500 U/ml 30 min (C) DP 500 mM 24 h
(D) DP 500 mM 24 h, then TNFa 500 U/ml 30 min, were assessed
for the presence of phospho-Ser 536 p65 antibody (Cell Signaling
Technology) byWestern blotting. The same blots were then stripped and
probed with antip65 antibody.
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and Semenza, 1993; Bowie et al, 1997). Given the dependence of
VCAM-1 expression on proteasomal degradation of the IkBa
regulatory subunit of NF-kB, it appeared to be reasonable to pre-
dict that ironchelatorsmight inhibitVCAM-1inductionbyTNFa.
Consistent with our hypothesis, the iron chelator DP almost
completely inhibited TNFa-mediated induction of VCAM-1 at
the protein and mRNA level.
Similar e¡ects upon TNFa-mediated induction of VCAM-1
were also observed in HDMEC with pretreatment using a di¡er-
ent iron speci¢c chelator, DFO. Addition of exogenous iron in
the form of ferric citrate to DFO before stimulation with TNFa
partially reversed the chelator e¡ect, supporting again iron bind-
ing as the target of action of iron chelators. The electron spin trap
5-dimethyl-1-pyrrolone-N-oxide (DMPO), which does not bind
to iron, failed to inhibit TNFa mediated induction of VCAM-1.
However, when HDMEC were treated with TEMPO, a nitrox-
ide spin trap that maintains iron as Fe3þ, and then stimulated
with TNFa, VCAM-1 induction was inhibited in a dose-depen-
dent fashion. These data further support the role of iron in
TNFa-mediated VCAM-1 up-regulation.
Our data clearly point to VCAM-1 gene transcription as a
target for DP. DP pretreatment completely blockedTNFamedia-
ted increases in VCAM-1 steady state mRNA expression, and
hnRNA induction. However, the exact mechanism of this e¡ect
is not completely de¢ned. Iron is required for activity of an intra-
cellular prolyl hydroxylase that modi¢es HIF-1a, facilitating its
interaction withVon Hippel Lindau protein and proteasomal de-
gradation (Ivan et al, 2001). Similarly, DFO has also been shown
to inhibit TNFa mediated IkBa degradation. We hypothesized
that iron chelation may inhibit VCAM-1 gene activation by
blocking TNFa-mediated IkBa degradation and NF-kB activa-
tion. However, iron chelators had no e¡ect on either NF-kB
translocation or the ability of translocated complexes to bind
to VCAM-1 kB elements, even at doses su⁄cient to block
VCAM-1 protein and mRNA expression. Given the lack of ob-
vious e¡ect of DP pretreatment on NF-kB binding to the
VCAM-1 kB element, other potential targets for iron chelators
had to be considered.
VCAM-1 expression has also been shown to be sensitive to
antioxidants such as n-acetylcysteine (NAC) and pyrrolidine-
dithiocarbamate (PDTC) (Marui et al, 1993). Agents such as
PDTC are also metal chelators, and it has been proposed that
their potent e¡ects may be mediated via a combination of metal
chelation and related antioxidant e¡ects (Saran and Bors, 1990). It
is possible that chelation of iron results in loss of metal dependent
redox signaling. However, our data does not support this expla-
nation since antioxidant mediated inhibition of VCAM-1 induc-
tion has been shown to be mediated via inhibition of NF-kB
activation and translocation, and DP had no e¡ect whatsoever
on NF-kB activation, translocation, or DNA binding (Bowie
et al, 1997).
Alternatively, iron chelators may inhibit VCAM-1 induction
by blocking the induction of IRF-1 expression. Previous studies
have suggested that although IRF-1 augments the expression of
VCAM-1 transcription, it is not necessary for gene expression
(Neish et al, 1995; Lechleitner et al, 1998). Our data are consistent
with these previous observations. Pretreatment of endothelial
cells with DP completely blocked TNFa-mediated induction of
IRF-1 expression. However, prior induction of IRF-1 by treat-
ment with IFNg only partially restored TNFa-mediated
VCAM-1 induction. Furthermore, DP pretreatment blocks TNFa
mediated up-regulation of ICAM-1 expression in HDMEC, a
process that is NF-kB dependent and IRF-1 independent (Gille
et al, 1997; Paxton et al, 1997).
It is possible that iron is required for NF-kB complexes to
transactivate theVCAM-1 gene without a¡ecting binding to sites
in the promoter as assessed by EMSA. Previous studies have
shown that anti-in£ammatory agents such as sulfasalazine inhibit
the p65 phosphorylation, and this phosphorylation is critical for
p65-mediated gene transactivation (Egan et al, 1999). The target
for phosphorylation may be one or more of a series of serine re-
sidues. Multiple enzymes, which induce phosphorylation of spe-
ci¢c serine residues, have been described (Wang and Baldwin,
1998; Wang et al, 2000). Our EMSA studies do not demonstrate
any global inhibition of NF-kB serine phosphorylation by DP.
In addition, iron chelators do not block TNFa-mediated phos-
phorylation of Ser536, a residue previously identi¢ed for its role
in p65 function (Sakurai et al, 1999). However, our studies cannot
rule out an e¡ect on phosphorylation of other residues such as
Ser529 (Wang and Baldwin, 1998;Wang et al, 2000). Iron may still
be critical for the phosphorylation of speci¢c serine residues in
p65, and altered patterns of phosphorylation may a¡ect VCAM-
1 gene transcription without a¡ecting translocation or DNA
binding.
Paradoxically, although DP did not a¡ect the activation of NF-
kB or its ability to bind in vitro to oligonucleotides corresponding
to VCAM-1 kB elements, it still almost completely blocked
VCAM-1 gene transcription mediated byTNFa. It is possible that
iron blocked VCAM-1 induction in HDMEC via a mechanism
completely independent of NF-kB. This is quite unlikely given
previous studies of TNFa mediated VCAM-1 gene expression in
this context showing a strict dependence on NF-kB (Iademarco
et al, 1992; Neish et al, 1995; Gille et al, 1996). An alternative
mechanism may be an iron dependent process regulating chro-
matin modi¢cations and accessibility. The e¡ects of iron chelators
on TNFa mediated genes in HDMEC are consistent with an
e¡ect on DNA packaging and histone modi¢cation.The di¡eren-
tial e¡ects onVCAM-1 and IkBa could be explained on the basis
of di¡erential requirements for chromatin remodeling as a pre-
requisite for transcription (Saccani et al, 2001). Certain NF-kB
driven genes are not immediately accessible and require modi¢-
cation of histones in addition to NF-kB translocation for expres-
sion. The transcription of these genes tends to be delayed after
cytokine stimulation and NF-kB activation, presumably because
histone modi¢cation requires additional time. In contrast, other
NF-kB driven genes such as IkBa are immediately accessible
and are rapidly induced after cytokine stimulation.We reasoned
that if iron was important for chromatin accessibility, iron chela-
tors should not have an e¡ect on genes such as IkBa that were
constitutively accessible while iron chelators should inhibit
expression of NF-kB inducible genes with delayed kinetics.
Our observations that DP pretreatment had no e¡ect on IkBa
Figure10. DP blocks TNFa mediated increases in IL-8 mRNA but
does not inhibit increases in IkBa mRNA: 5A32 HDMEC were sti-
mulated with TNFa (1000 U/ml 4 h) with and without pretreatment
with DP (1000 mM 24 h). Steady state levels of IL-8 and IkBa mRNA
were assessed by real-time quantitative PCR as described in material and
methods. Levels are expressed as fold-increase over unstimulated, untreated
controls.
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induction, while consistently blocking other NF-kB inducible
genes with delayed kinetics, support this hypothesis.
Previous studies linking chromatin remodeling to iron also
provide additional indirect evidence for the role of iron. Iron is
essential for expression of a number of genes critical for cell
growth and proliferation, and removal of iron via the use of DFO
has e¡ects that are similar to the e¡ects of histone deacetylase
(HDAC) (Kim et al, 2001) (Kramer et al, 2002). Treatment of cells
with DFO resulted in cell cycle arrest and down-regulation of
p21WAF and speci¢c cyclin dependent kinases. From these data,
one can conclude that expression of p21WAF is iron dependent
(Kramer et al, 2002). Similarly, HDAC inhibition resulted in gene
expression comparable to iron loading, with resultant expression
of p21WAF and cell proliferation (Kim et al, 2001). Consistent with
our hypothesis is the converse of these observations. Histone
deacetylation has e¡ects that are essentially identical to iron
chelation. It is reasonable to propose that they may operate
via a common mechanism and that mechanism likely involves
chromatin accessibility.
In conclusion, iron chelators inhibited VCAM-1 protein
and mRNA induction in a concentration- and time-dependent
manner via a mechanism that appears to be transcriptionally
mediated. The target of iron chelator e¡ects was not NF-kB
activation, but appeared to be mediated through a combination
of inhibition of IRF-1 expression and e¡ects on the ability of
translocated NF-kB complexes to transactivate the VCAM-1
gene, potentially via iron dependent alterations in chromatin
remodeling.
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